External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry

Archive ouverte

Boucly, Athénaïs | Weatherald, Jason | Savale, Laurent | de Groote, Pascal | Cottin, Vincent | Prévot, Grégoire | Chaouat, Ari | Picard, François | Horeau-Langlard, Delphine | Bourdin, Arnaud | Jutant, Etienne-Marie | Beurnier, Antoine | Jevnikar, Mitja | Jaïs, Xavier | Simonneau, Gérald | Montani, David | Sitbon, Olivier | Humbert, Marc

Edité par CCSD ; European Respiratory Society -

International audience. Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate, or high-risk. A minority of patients achieve low-risk status with most remaining intermediate-risk. Our aim was to validate a 4-strata risk assessment approach categorising patients as low, intermediate-low, intermediate-high, or high risk, as proposed by the COMPERA Registry investigators. Methods We evaluated incident patients from the French PAH Registry and applied a 4-strata risk method at baseline and at first reassessment. We applied refined cut-points for 3 variables: World Health Organization functional class, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide. We used Kaplan-Meier survival analyses and Cox proportional hazards regression to assess survival according to a 3-strata and 4-strata risk approach. Results At baseline (n=2879), the 4-strata approach identified 4 distinct risk groups and performed better than a 3-strata method for predicting mortality. The 4-strata model discrimination was higher than the 3-strata method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease, and portopulmonary hypertension. Using the 4-strata approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the 3-strata approach. Those who achieved or maintained a low-risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high. Conclusions The 4-strata risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the 3-strata approach.

Suggestions

Du même auteur

Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension

Archive ouverte | Boucly, Athénaïs | CCSD

International audience. Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of p...

COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study

Archive ouverte | Montani, David | CCSD

International audience. Rationale: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of cor...

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

Archive ouverte | Boucly, Athénaïs | CCSD

International audience

Chargement des enrichissements...